CO2018005915A2 - Aglutinantes de tnf mejorados - Google Patents
Aglutinantes de tnf mejoradosInfo
- Publication number
- CO2018005915A2 CO2018005915A2 CONC2018/0005915A CO2018005915A CO2018005915A2 CO 2018005915 A2 CO2018005915 A2 CO 2018005915A2 CO 2018005915 A CO2018005915 A CO 2018005915A CO 2018005915 A2 CO2018005915 A2 CO 2018005915A2
- Authority
- CO
- Colombia
- Prior art keywords
- tnf
- isvd
- polypeptides
- bind
- compounds
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 3
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Organic Insulating Materials (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
La presente invención se refiere a secuencias de aminoácidos, compuestos y polipéptidos que se unen al factor de necrosis tumoral alfa ("TNF" o "TNF-alfa"). En particular, la presente invención se refiere a dominios variables únicos de inmunoglobulina de cadena pesada mejorados (también denominados aquí como "ISV" o "ISVD") que se unen al factor de necrosis tumoral alfa, así como a proteínas, polipéptidos y otros constructos, compuestos, moléculas o entidades químicas que comprenden tales ISVD, colectivamente aglutinantes de TNF. Otros aspectos, realizaciones, características, usos y ventajas de la invención serán claros para el experto en la materia con base en la descripción en este documento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562254375P | 2015-11-12 | 2015-11-12 | |
PCT/EP2016/077595 WO2017081320A1 (en) | 2015-11-12 | 2016-11-14 | Improved tnf binders |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018005915A2 true CO2018005915A2 (es) | 2018-06-20 |
Family
ID=57348648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0005915A CO2018005915A2 (es) | 2015-11-12 | 2018-06-08 | Aglutinantes de tnf mejorados |
Country Status (36)
Country | Link |
---|---|
US (2) | US10544211B2 (es) |
EP (2) | EP3266798A3 (es) |
JP (2) | JP6962915B2 (es) |
KR (2) | KR102641194B1 (es) |
CN (1) | CN108473563B (es) |
AU (2) | AU2016352943B2 (es) |
BR (1) | BR112018009714A8 (es) |
CA (2) | CA3005085A1 (es) |
CL (1) | CL2018001291A1 (es) |
CO (1) | CO2018005915A2 (es) |
CR (1) | CR20180311A (es) |
CY (1) | CY1120303T1 (es) |
DK (1) | DK3191511T3 (es) |
DO (1) | DOP2018000122A (es) |
EC (1) | ECSP18042569A (es) |
ES (1) | ES2662418T3 (es) |
GT (1) | GT201800095A (es) |
HK (1) | HK1248716A1 (es) |
HR (1) | HRP20171949T1 (es) |
HU (1) | HUE035805T2 (es) |
IL (2) | IL310373A (es) |
LT (1) | LT3191511T (es) |
MA (1) | MA41653A (es) |
MD (1) | MD3191511T2 (es) |
ME (1) | ME02954B (es) |
MX (1) | MX2018005992A (es) |
NO (1) | NO2768984T3 (es) |
PE (1) | PE20181317A1 (es) |
PH (1) | PH12018501025A1 (es) |
PL (1) | PL3191511T3 (es) |
PT (1) | PT3191511T (es) |
RS (1) | RS56676B1 (es) |
SG (1) | SG11201803975SA (es) |
SI (1) | SI3191511T1 (es) |
TN (1) | TN2018000159A1 (es) |
WO (1) | WO2017081320A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
KR102240318B1 (ko) | 2011-06-23 | 2021-04-15 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
US20170121399A1 (en) | 2014-05-16 | 2017-05-04 | Ablynx N.V. | Improved immunoglobulin variable domains |
NO2768984T3 (es) * | 2015-11-12 | 2018-06-09 | ||
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
KR20220122652A (ko) | 2019-12-06 | 2022-09-02 | 아블린쓰 엔.브이. | TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
CN114980923A (zh) | 2019-12-06 | 2022-08-30 | 艾伯霖克斯公司 | 包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽 |
CN112300289B (zh) * | 2019-12-30 | 2022-06-10 | 中国药科大学 | RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用 |
WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
WO2024097571A1 (en) * | 2022-11-04 | 2024-05-10 | St. Jude Children's Research Hospital, Inc. | Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases |
WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE427968T1 (de) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | Immunoglobuline ohne leichtkette |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
AU2152299A (en) | 1997-10-27 | 1999-05-24 | Unilever Plc | Multivalent antigen-binding proteins |
WO1999042077A2 (en) | 1998-02-19 | 1999-08-26 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
JP2006520584A (ja) * | 2002-11-08 | 2006-09-14 | アブリンクス エン.ヴェー. | 安定化単一ドメイン抗体 |
JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン.ヴェー. | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
DE60334645D1 (de) | 2003-11-07 | 2010-12-02 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
JP5113523B2 (ja) | 2004-10-13 | 2013-01-09 | アブリンクス ナームローゼ フェンノートシャップ | アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体TMを含むポリペプチド |
EP1863847A2 (en) | 2004-12-02 | 2007-12-12 | Domantis Limited | Anti-il-1r1 single domain antibodies and therapeutic uses |
DK2949668T3 (da) * | 2005-05-18 | 2019-11-11 | Ablynx Nv | Forbedrede nanobodies tm mod tumornekrosefaktor-alfa |
EP2444424B1 (en) | 2005-05-20 | 2018-08-08 | Ablynx N.V. | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
DE102005023617A1 (de) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
ES2626610T3 (es) | 2005-08-30 | 2017-07-25 | Intrexon Actobiotics Nv | Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal |
WO2007063308A2 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
BRPI0619224A2 (pt) | 2005-12-01 | 2017-06-20 | Domantis Ltd | monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória |
FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
EP1976991A1 (en) | 2006-01-24 | 2008-10-08 | Domantis Limited | Fusion proteins that contain natural junctions |
WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
JP2010511397A (ja) | 2006-12-05 | 2010-04-15 | アブリンクス エン.ヴェー. | 血清タンパク質と結合可能なペプチド |
KR20120125601A (ko) | 2007-05-24 | 2012-11-16 | 아블린쓰 엔.브이. | Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드 |
WO2009068630A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Immunoglobulin constructs |
DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
CN102099378B (zh) | 2008-05-16 | 2016-01-20 | 埃博灵克斯股份有限公司 | 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽 |
EP2398827A2 (en) * | 2009-02-19 | 2011-12-28 | Glaxo Group Limited | Improved anti-tnfr1 polypeptides, antibody variable domains&antagonists |
AU2010233658B2 (en) | 2009-04-10 | 2013-11-28 | Ablynx Nv | Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders |
WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
AU2010272590B2 (en) | 2009-07-16 | 2013-10-10 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
WO2012175400A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Serum albumin binding proteins |
US20150158948A9 (en) | 2011-03-28 | 2015-06-11 | Francis Descamps | Bispecific anti-cxcr7 immunoglobulin single variable domains |
KR102240318B1 (ko) * | 2011-06-23 | 2021-04-15 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
ES2813432T3 (es) * | 2011-08-17 | 2021-03-23 | Glaxo Group Ltd | Proteínas y péptidos modificados |
WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
US20170121399A1 (en) * | 2014-05-16 | 2017-05-04 | Ablynx N.V. | Improved immunoglobulin variable domains |
NO2768984T3 (es) * | 2015-11-12 | 2018-06-09 |
-
2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
-
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en active Pending
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active IP Right Grant
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 CA CA3005085A patent/CA3005085A1/en active Pending
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Application Filing
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active Search and Examination
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
- 2016-11-14 MX MX2018005992A patent/MX2018005992A/es unknown
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en active Application Filing
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
-
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/zh unknown
- 2017-12-15 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
-
2018
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
-
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
-
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018005915A2 (es) | Aglutinantes de tnf mejorados | |
PH12017502129A1 (en) | Antibodies against ox40 and uses thereof | |
MX2023003630A (es) | Aglutinantes de albumina de suero mejorados. | |
ECSP19011185A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123 | |
PH12016502267A1 (en) | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof | |
EA201891121A1 (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения | |
EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
EA201892386A1 (ru) | Химерные нейротоксины | |
UY36561A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
MX371403B (es) | Moleculas de andamiaje a base de fibronectina estabilizada. | |
MX2021000155A (es) | Moleculas de proteina multifuncionales que comprenden decorina y su uso. | |
GEP20217307B (en) | ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF | |
EA201400924A1 (ru) | Сконструированные пестицидные белки | |
AR103586A1 (es) | Proteínas quiméricas que mejoran la actividad de los dominios de unión a adn y factores de transcripción en plantas | |
ES2526109R2 (es) | Péptido y composición farmacéutica para el tratamiento del cáncer | |
MX2022003507A (es) | Modulos de union que comprenden dominios ehd2 modificados. | |
EA201991088A1 (ru) | Связывающие пептиды | |
EA202090533A2 (ru) | Антитела к ox40 и их применение |